
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6178111/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neighborhood Socioeconomic Disadvantage and 30-Day Rehospitalization. Annals of Internal Medicine, 2014, 161, 765.	2.0	816
2	Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/â^'- and c-kit-Dependent Bone Marrow. Cell, 2008, 135, 437-448.	13.5	325
3	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. JAMA Oncology, 2017, 3, 1663.	3.4	219
4	CARM1 Methylates Chromatin Remodeling Factor BAF155 to Enhance Tumor Progression and Metastasis. Cancer Cell, 2014, 25, 21-36.	7.7	215
5	Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2012, 30, 4416-4426.	0.8	197
6	Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncology, The, 2012, 13, 1218-1224.	5.1	195
7	Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncology, The, 2016, 17, 1612-1620.	5.1	182
8	Advanced cognitive training for breast cancer survivors: a randomized controlled trial. Breast Cancer Research and Treatment, 2012, 135, 799-809.	1.1	175
9	Prevalence of Human Papillomavirus in Oropharyngeal Cancer. Cancer Journal (Sudbury, Mass), 2015, 21, 138-146.	1.0	168
10	Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood, 2005, 105, 3737-3742.	0.6	147
11	Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Research, 2017, 19, 9.	2.2	104
12	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 1797-1806.	0.8	102
13	Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. European Urology, 2018, 73, 751-759.	0.9	99
14	Association of Neighborhood-Level Disadvantage With Alzheimer Disease Neuropathology. JAMA Network Open, 2020, 3, e207559.	2.8	92
15	Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Human Molecular Genetics, 2006, 15, 2837-2845.	1.4	89
16	Development and Characterization of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinoma Tumorgrafts. Clinical Cancer Research, 2013, 19, 855-864.	3.2	85
17	Prevalence of Human Papillomavirus in Oropharyngeal Squamous Cell Carcinoma in the United States Across Time. Chemical Research in Toxicology, 2014, 27, 462-469.	1.7	80
18	Gemcitabine, Cisplatin, and Sunitinib for Metastatic Urothelial Carcinoma and as Preoperative Therapy for Muscle-Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2013, 11, 175-181.	0.9	78

#	Article	IF	CITATIONS
19	A General Statistical Framework for Subgroup Identification and Comparative Treatment Scoring. Biometrics, 2017, 73, 1199-1209.	0.8	75
20	The Presence of Cyclooxygenase 2, Tumor-Associated Macrophages, and Collagen Alignment as Prognostic Markers for Invasive Breast Carcinoma Patients. American Journal of Pathology, 2018, 188, 559-573.	1.9	75
21	Individual Prediction in Prostate Cancer Studies Using a Joint Longitudinal Survival–Cure Model. Journal of the American Statistical Association, 2008, 103, 178-187.	1.8	74
22	NF-κB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy. Cancer Letters, 2009, 278, 145-155.	3.2	67
23	Radiation Dose Escalation in Esophageal Cancer Revisited: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. International Journal of Radiation Oncology Biology Physics, 2016, 96, 985-993.	0.4	67
24	Phase II Trial of Erlotinib and Docetaxel in Advanced and Refractory Hepatocellular and Biliary Cancers: Hoosier Oncology Group Gl06-101. Oncologist, 2012, 17, 13-e23.	1.9	66
25	Bias and Efficiency Loss Due to Categorizing an Explanatory Variable. Journal of Multivariate Analysis, 2002, 83, 248-263.	0.5	63
26	A Phase II Study of Gemcitabine in Combination With Radiation Therapy in Patients With Localized, Unresectable, Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 460-465.	0.6	60
27	Regularized outcome weighted subgroup identification for differential treatment effects. Biometrics, 2015, 71, 645-653.	0.8	57
28	Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis. Cancer Treatment Reviews, 2012, 38, 919-925.	3.4	53
29	Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group. Journal of Thoracic Oncology, 2010, 5, 2008-2011.	0.5	46
30	Survival in patients with pancreatic cancer after the diagnosis of malignant ascites or liver metastases by EUS-FNA. Gastrointestinal Endoscopy, 2010, 71, 260-265.	0.5	46
31	Ethanol-Induced Alterations in Fatty Acid-Related Lipids in Serum and Tissues in Mice. Alcoholism: Clinical and Experimental Research, 2011, 35, 229-234.	1.4	46
32	Paced Respiration for Vasomotor and Other Menopausal Symptoms: A Randomized, Controlled Trial. Journal of General Internal Medicine, 2013, 28, 193-200.	1.3	40
33	On the effect of electronic patient portal on primary care utilization and appointment adherence. BMC Medical Informatics and Decision Making, 2018, 18, 84.	1.5	40
34	Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. Urology, 2002, 60, 276-280.	0.5	38
35	Risk factors, pathophysiology, and treatment of hot flashes in cancer. Ca-A Cancer Journal for Clinicians, 2013, 63, 167-192.	157.7	38
36	Censored linear regression for case-cohort studies. Biometrika, 2006, 93, 747-762.	1.3	33

#	Article	IF	CITATIONS
37	Association of Neighborhood Context, Cognitive Decline, and Cortical Change in an Unimpaired Cohort. Neurology, 2021, 96, e2500-e2512.	1.5	32
38	Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2341-2350.	1.2	30
39	Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study. Journal of Thoracic Oncology, 2009, 4, 93-96.	0.5	29
40	Increased c-Jun Expression and Reduced GATA2 Expression Promote Aberrant Monocytic Differentiation Induced by Activating <i>PTPN11</i> Mutants. Molecular and Cellular Biology, 2009, 29, 4376-4393.	1.1	28
41	Prior event rate ratio adjustment: numerical studies of a statistical method to address unrecognized confounding in observational studies. Pharmacoepidemiology and Drug Safety, 2012, 21, 60-68.	0.9	28
42	A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Investigational New Drugs, 2013, 31, 1307-1310.	1.2	27
43	Thirty-Day Re-observation, Chronic Re-observation, and Neighborhood Disadvantage. Mayo Clinic Proceedings, 2020, 95, 2644-2654.	1.4	27
44	Metaâ€analysis based variable selection for gene expression data. Biometrics, 2014, 70, 872-880.	0.8	26
45	Identification of subgroups with differential treatment effects for longitudinal and multiresponse variables. Statistics in Medicine, 2016, 35, 4837-4855.	0.8	26
46	Risk of Advanced Neoplasia Using the National Cancer Institute's Colorectal Cancer Risk Assessment Tool. Journal of the National Cancer Institute, 2017, 109, .	3.0	25
47	Ras Dependent Paracrine Secretion of Osteopontin by Nf1+/â^' Osteoblasts Promote Osteoclast Activation in a Neurofibromatosis Type I Murine Model. Pediatric Research, 2009, 65, 613-618.	1.1	24
48	A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Investigational New Drugs, 2009, 27, 565-570.	1.2	23
49	Survival Outcomes for Patients With T3N0M0 Squamous Cell Carcinoma of the Glottic Larynx. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 1126.	1.2	23
50	Risk of Synchronous Distant Recurrence at Time of Locoregional Recurrence in Patients With Stage II and III Breast Cancer (AFT-01). Journal of Clinical Oncology, 2018, 36, 975-980.	0.8	23
51	Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer. JAMA Oncology, 2021, 7, 1644.	3.4	21
52	Gefitinib Plus Celecoxib in Chemotherapy-NaÃ ⁻ ve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology, 2008, 3, 374-379.	0.5	20
53	A Phase I and Pharmacokinetic Trial of Erlotinib in Combination with Weekly Docetaxel in Patients with Taxane-Naive Malignancies. Clinical Cancer Research, 2008, 14, 1131-1137.	3.2	20
54	A new "Comparative Effectiveness―assessment strategy using the THIN database: comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiology and Drug Safety, 2013, 22, 86-97.	0.9	20

#	Article	IF	CITATIONS
55	Prediction of coronary artery disease risk based on multiple longitudinal biomarkers. Statistics in Medicine, 2016, 35, 1299-1314.	0.8	20
56	Drug–drug interaction prediction: a Bayesian meta-analysis approach. Statistics in Medicine, 2007, 26, 3700-3721.	0.8	19
57	Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression. Metabolomics, 2013, 9, 202-212.	1.4	19
58	Chemoprotective Effects of Dietary Grape Powder on UVB Radiation-Mediated Skin Carcinogenesis in SKH-1 Hairless Mice. Journal of Investigative Dermatology, 2019, 139, 552-561.	0.3	19
59	Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC): A Phase I/II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology, 2009, 4, 1420-1424.	0.5	18
60	Genetic disruption of the PI3K regulatory subunits, p85Â, p55Â, and p50Â, normalizes mutant PTPN11-induced hypersensitivity to GM-CSF. Haematologica, 2012, 97, 1042-1047.	1.7	17
61	A Phase II Study with Cetuximab and Radiation Therapy for Patients with Surgically Resectable Esophageal and GE Junction Carcinomas: Hoosier Oncology Group G05-92. Journal of Thoracic Oncology, 2013, 8, 1425-1429.	0.5	17
62	Semiparametric regression on cumulative incidence function with interval ensored competing risks data. Statistics in Medicine, 2017, 36, 3683-3707.	0.8	17
63	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. Neuro-Oncology, 2019, 21, 1141-1149.	0.6	17
64	Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53. Cancer Chemotherapy and Pharmacology, 2012, 70, 25-32.	1.1	16
65	Hospice Enrollment, Local Hospice Utilization Patterns, and Rehospitalization in Medicare Patients. Journal of Palliative Medicine, 2015, 18, 601-612.	0.6	15
66	Cardiac Toxicity in Operable Esophageal Cancer Patients Treated With or Without Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 662-667.	0.6	15
67	Joint models for multiple longitudinal processes and time-to-event outcome. Journal of Statistical Computation and Simulation, 2016, 86, 3682-3700.	0.7	14
68	Risk Prediction for Heterogeneous Populations with Application to Hospital Admission Prediction. Biometrics, 2018, 74, 557-565.	0.8	14
69	Clinical outcomes for patients presenting with N3 head and neck squamous cell carcinoma: Analysis of the National Cancer Database. Head and Neck, 2017, 39, 2159-2170.	0.9	13
70	A Robust Approach to Sample Size Calculation in Cancer Immunotherapy Trials with Delayed Treatment Effect. Biometrics, 2018, 74, 1292-1300.	0.8	13
71	Risk from delayed or missed care and <scp>nonâ€COVID</scp> â€19 outcomes for older patients with chronic conditions during the pandemic. Journal of the American Geriatrics Society, 2022, 70, 1314-1324.	1.3	13
72	A hybrid Newton-type method for censored survival data using double weights in linear models. Lifetime Data Analysis, 2006, 12, 345-364.	0.4	12

#	Article	IF	CITATIONS
73	Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77. Clinical Lung Cancer, 2013, 14, 224-229.	1.1	12
74	Strategies Used and Data Obtained During Treatment Fidelity Monitoring. Nursing Research, 2013, 62, 59-65.	0.8	12
75	Bayesian approach for flexible modeling of semicompeting risks data. Statistics in Medicine, 2014, 33, 5111-5125.	0.8	12
76	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2022, 40, 3633-3641.	0.8	12
77	Evaluating the role of serotonin in hot flashes after breast cancer using acute tryptophan depletion. Menopause, 2009, 16, 644-652.	0.8	11
78	Regression Calibration in Semiparametric Accelerated Failure Time Models. Biometrics, 2010, 66, 405-414.	0.8	11
79	A Bayesian Meta-Analysis on Published Sample Mean and Variance Pharmacokinetic Data with Application to Drug–Drug Interaction Prediction. Journal of Biopharmaceutical Statistics, 2008, 18, 1063-1083.	0.4	10
80	Perceived Control and Hot Flashes in Treatment-Seeking Breast Cancer Survivors and Menopausal Women. Cancer Nursing, 2012, 35, 195-202.	0.7	10
81	Stat3 Downstream Gene Product Chitinase 3-Like 1 Is a Potential Biomarker of Inflammation-induced Lung Cancer in Multiple Mouse Lung Tumor Models and Humans. PLoS ONE, 2013, 8, e61984.	1.1	10
82	Somatosensory amplification and menopausal symptoms in breast cancer survivors and midlife women. Maturitas, 2014, 78, 51-55.	1.0	10
83	Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs. BMC Medical Research Methodology, 2015, 15, 48.	1.4	10
84	A Computational-Based Approach to Identify Estrogen Receptor <i>α</i> / <i>β</i> Heterodimer Selective Ligands. Molecular Pharmacology, 2018, 93, 197-207.	1.0	10
85	The importance of health insurance claims data in creating learning health systems: evaluating care for high-need high-cost patients using the National Patient-Centered Clinical Research Network (PCORNet). Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 1305-1313.	2.2	10
86	A practical model for research with learning health systems: Building and implementing effective complex case management. Applied Ergonomics, 2020, 84, 103023.	1.7	9
87	HPV impacts survival of stage IVC non-oropharyngeal HNSCC cancer patients. Otorhinolaryngology-head and Neck Surgery, 2017, 2, .	0.1	8
88	A National Study of the Use of Asymptomatic Systemic Imaging for Surveillance Following Breast Cancer Treatment (AFT-01). Annals of Surgical Oncology, 2018, 25, 2587-2595.	0.7	8
89	One Quarter of Medicare Hospitalizations in Patients with Systemic Lupus Erythematosus Readmitted within Thirty Days. Seminars in Arthritis and Rheumatism, 2021, 51, 477-485.	1.6	8
90	Group Variable Selection via Convex Log-Exp-Sum Penalty with Application to a Breast Cancer Survivor Study. Biometrics, 2015, 71, 53-62.	0.8	7

#	Article	IF	CITATIONS
91	Sample size under the additive hazards model. Clinical Trials, 2016, 13, 188-198.	0.7	7
92	A Semiparametric Approach to Model Effect Modification. Journal of the American Statistical Association, 2022, 117, 752-764.	1.8	7
93	Differential CARM1 Isoform Expression in Subcellular Compartments and among Malignant and Benign Breast Tumors. PLoS ONE, 2015, 10, e0128143.	1.1	6
94	Utility of Clinical Breast Examinations in Detecting Local–Regional Breast Events After Breast-Conservation in Women with a Personal History of High-Risk Breast Cancer. Annals of Surgical Oncology, 2016, 23, 3385-3391.	0.7	6
95	Optimal Treatment Assignment to Maximize Expected Outcome with Multiple Treatments. Biometrics, 2018, 74, 506-516.	0.8	6
96	Adjuvant immunotherapy in patients with highâ€risk muscleâ€invasive urothelial carcinoma: The potential impact of informative censoring. Cancer, 2022, 128, 2892-2897.	2.0	6
97	Buckley–James Type Estimator for Censored Data with Covariates Missing by Design. Scandinavian Journal of Statistics, 2011, 38, 252-267.	0.9	5
98	Fused comparative intervention scoring for heterogeneity of longitudinal intervention effects. Annals of Applied Statistics, 2019, 13, .	0.5	5
99	Impact of initial chemotherapy regimen on outcomes for patients with doubleâ€expressor lymphoma: A multiâ€center analysis. Hematological Oncology, 2021, 39, 473-482.	0.8	5
100	Buckley–James-type of estimators under the classical case cohort design. Annals of the Institute of Statistical Mathematics, 2007, 59, 675-695.	0.5	4
101	Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). Journal of Geriatric Oncology, 2014, 5, 230-237.	0.5	4
102	Advanced colorectal neoplasia risk stratification by penalized logistic regression. Statistical Methods in Medical Research, 2016, 25, 1677-1691.	0.7	4
103	Impact of sufficient dimension reduction in nonparametric estimation of causal effect. Statistical Theory and Related Fields, 2018, 2, 89-95.	0.2	4
104	Instrumental Variable Based Estimation Under the Semiparametric Accelerated Failure Time Model. Biometrics, 2019, 75, 516-527.	0.8	4
105	Prospective Study of PET/MRI Tumor Response During Chemoradiotherapy for Patients With Low-risk and Intermediate-risk p16-positive Oropharynx Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 202-207.	0.6	4
106	Evaluating the Role of Serotonin on Neuropsychological Function After Breast Cancer Using Acute Tryptophan Depletion. Biological Research for Nursing, 2012, 14, 5-15.	1.0	3
107	Improving estimation efficiency for semi-competing risks data with partially observed terminal event. Journal of Nonparametric Statistics, 2016, 28, 860-874.	0.4	3
108	Cox regression with survivalâ€ŧimeâ€dependent missing covariate values. Biometrics, 2020, 76, 460-471.	0.8	3

#	Article	IF	CITATIONS
109	Marginal and Conditional Distribution Estimation from Doubleâ€sampled Semiâ€competing Risks Data. Scandinavian Journal of Statistics, 2015, 42, 87-103.	0.9	2
110	A new method to address unmeasured confounding of mortality in observational studies. Learning Health Systems, 2017, 1, e10016.	1.1	2
111	Treatment recommendation and parameter estimation under single-index contrast function. Statistical Theory and Related Fields, 2017, 1, 171-181.	0.2	2
112	Designing cost-efficient randomized trials by using flexible recruitment strategies. BMC Medical Research Methodology, 2012, 12, 106.	1.4	1
113	Testing and Sample Size for Polygonal One-Sided Hypotheses on Bivariate Binary Outcomes. Statistics in Biopharmaceutical Research, 2013, 5, 1-17.	0.6	1
114	A statistical framework for pathway and gene identification from integrative analysis. Journal of Multivariate Analysis, 2017, 156, 1-17.	0.5	1
115	Analysis and Design of Clinical Trials Using Additive Hazards Survival Endpoints. Statistics in Biopharmaceutical Research, 2019, 11, 274-282.	0.6	1
116	Quantile treatment effect estimation with dimension reduction. Statistical Theory and Related Fields, 2020, 4, 202-213.	0.2	1
117	Sample Size Determination for Stratified Phase II Cancer Trials With Monotone Order Constraints. Statistics in Biopharmaceutical Research, 2021, 13, 425-434.	0.6	1
118	Tailored interventions to reduce hospital admissions for individuals with cerebral palsy. Developmental Medicine and Child Neurology, 2020, 62, 889-889.	1.1	1
119	Diagnosis-group-specific transitional care program recommendations for 30-day rehospitalization reduction. Annals of Applied Statistics, 2021, 15, .	0.5	1
120	A generalizability score for aggregate causal effect. Biostatistics, 2023, 24, 309-326.	0.9	1
121	Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. Cureus, 2022, 14, e23783.	0.2	1
122	Discussion of "Combining biomarkers to optimize patient treatment recommendations―by Chaeryon Kang, Holly Janes, and Ying Huang. Biometrics, 2014, 70, 716-719.	0.8	0
123	Personalised treatment assignment maximising expected benefit with smooth hinge loss. Statistical Theory and Related Fields, 2017, 1, 37-47.	0.2	0
124	Tailored optimal posttreatment surveillance for cancer recurrence. Biometrics, 2021, 77, 942-955.	0.8	0
125	Structure-preserving integrated analysis for risk stratification with application to cancer staging. Biostatistics, 2021, , .	0.9	0
126	Sufficient dimension reduction for populations with structured heterogeneity. Biometrics, 2022, 78, 1626-1638.	0.8	0

#	Article	IF	CITATIONS
127	Costimulatory Effects of Interleukin-18 (IL-18) on Human Natural Killer (NK) Cells Activated through Fc Receptors for Immunoglobulin (IgG). Blood, 2010, 116, 2780-2780.	0.6	Ο
128	The Protein Tyrosine Phosphatase, Shp2, Positively Contributes to FLT3-ITD-Induced Malignant Disease in Vivo and Co-Localizes with Nuclear Phospho-STAT5 in FLT3-ITD-Expressing Leukemic Cells Blood, 2012, 120, 2420-2420.	0.6	0
129	Optimal treatment assignment of multiple treatments with analysis of variance decomposition. Statistics and Its Interface, 2019, 12, 355-363.	0.2	0
130	Optimal treatment assignment of multiple treatments with analysis of variance decomposition. Statistics and Its Interface, 2019, 12, 355-363.	0.2	0
131	Tcof1 haploinsufficiency promotes early T cell precursor-like leukemia in NrasQ61R/+ mice. Leukemia, 2022, , .	3.3	Ο
132	Impactability Modeling for Reducing Medicare Accountable Care Organization Payments and Hospital Events in High-Need High-Cost Patients: Longitudinal Cohort Study. Journal of Medical Internet Research, 2022, 24, e29420.	2.1	0